Compare Regeneron Pharmaceuticals Inc (REGN) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Stanley Black & Decker, Inc. — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Stanley Black & Decker, Inc. trades at $91.6 (market cap $14.17B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.9× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.58%). Which is the better fit depends on your goals.
| REGN | SWK | |
|---|---|---|
Market Cap | $83.43B | $14.17B |
Sector | Health | — |
52-Week High | $852.03 | $104.00 |
52-Week Low | $555.51 | $62.12 |
Enterprise Value | $78.14B | $18.33B |
Dividend Yield | 0.46% | 3.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Stanley Black & Decker (SWK) trades at $93.81, down 3.65% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and management has raised 2026 EPS guidance to $4.60-$5.45. Recent portfolio optimization includes the sale of Excel Industries to Bad Boy Mowers, focusing on core brands. Valuation metrics appear reasonable with P/E of 22.94 and P/S of 0.93, while analyst consensus price target sits at $98.50 with 43% buy ratings.
SWK presents a mixed outlook with strong earnings momentum and cost transformation benefits offset by bearish technical indicators. The stock offers value potential with upside to analyst targets and dividend income, but faces execution risks in margin expansion and industrial demand volatility. Near-term support at $90 provides a key level to watch amid current market weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
